Xiu‐Xian Wu

590 total citations
26 papers, 482 citations indexed

About

Xiu‐Xian Wu is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Xiu‐Xian Wu has authored 26 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Xiu‐Xian Wu's work include Cell death mechanisms and regulation (12 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Hepatitis B Virus Studies (5 papers). Xiu‐Xian Wu is often cited by papers focused on Cell death mechanisms and regulation (12 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Hepatitis B Virus Studies (5 papers). Xiu‐Xian Wu collaborates with scholars based in Japan, China and United States. Xiu‐Xian Wu's co-authors include Yoshiyuki Kakehi, Osamu Ogawa, Xinghua Jin, Osamu Yoshida, Youichi Mizutani, Osamu Ogawa, Yu Zeng, Toshiro Terachi, Yoichi Mizutani and Hiroyuki Tsunemori and has published in prestigious journals such as Clinical Cancer Research, The Journal of Urology and Urology.

In The Last Decade

Xiu‐Xian Wu

26 papers receiving 477 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiu‐Xian Wu Japan 13 295 144 71 66 58 26 482
Malcolm Mason United Kingdom 14 315 1.1× 151 1.0× 214 3.0× 80 1.2× 42 0.7× 28 670
Ralph A. Highshaw United States 10 450 1.5× 131 0.9× 118 1.7× 55 0.8× 126 2.2× 13 685
Qingxiang Gao China 13 254 0.9× 84 0.6× 67 0.9× 124 1.9× 25 0.4× 43 503
Sam Tilborghs Belgium 5 262 0.9× 179 1.2× 30 0.4× 124 1.9× 52 0.9× 14 530
Hannes Zwickl Austria 14 223 0.8× 65 0.5× 56 0.8× 68 1.0× 59 1.0× 20 469
Fengzhou Li China 14 302 1.0× 157 1.1× 22 0.3× 149 2.3× 49 0.8× 26 542
Lu Hao China 13 321 1.1× 131 0.9× 63 0.9× 123 1.9× 30 0.5× 50 548
Margaretha A. Skowron Germany 16 298 1.0× 111 0.8× 202 2.8× 73 1.1× 52 0.9× 32 530
Mingjing He China 16 443 1.5× 194 1.3× 61 0.9× 95 1.4× 74 1.3× 26 723

Countries citing papers authored by Xiu‐Xian Wu

Since Specialization
Citations

This map shows the geographic impact of Xiu‐Xian Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiu‐Xian Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiu‐Xian Wu more than expected).

Fields of papers citing papers by Xiu‐Xian Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiu‐Xian Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiu‐Xian Wu. The network helps show where Xiu‐Xian Wu may publish in the future.

Co-authorship network of co-authors of Xiu‐Xian Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiu‐Xian Wu. A scholar is included among the top collaborators of Xiu‐Xian Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiu‐Xian Wu. Xiu‐Xian Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Xiu‐Xian, Akihiro Kanematsu, Yuki Kita, et al.. (2023). Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner. Oncology Reports. 51(1). 2 indexed citations
2.
Wu, Xiu‐Xian, Xinghua Jin, Akihiro Kanematsu, et al.. (2022). Apigenin inhibits renal cell carcinoma cell proliferation through G2/M phase cell cycle arrest. Oncology Reports. 47(3). 21 indexed citations
3.
Li, Yongnan, Xiu‐Xian Wu, Xinghua Jin, et al.. (2016). Enhancement of death receptor 4-mediated apoptosis and cytotoxicity in renal cell carcinoma cells by anisomycin. Anti-Cancer Drugs. 28(2). 180–186. 8 indexed citations
4.
Ahmed, Syed Minhaj Uddin, Xiu‐Xian Wu, Xinghua Jin, et al.. (2014). Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. Oncology Reports. 33(2). 566–572. 10 indexed citations
5.
Li, Jinhua, Xinghua Jin, Jianbo Yu, et al.. (2012). Expression of TRAIL, DR4, and DR5 in Bladder Cancer: Correlation With Response to Adjuvant Therapy and Implications of Prognosis. Urology. 79(4). 968.e7–968.e15. 33 indexed citations
6.
7.
Li, Yongnan, Xiaoxia Li, Xiaodong Sun, et al.. (2009). Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer. British Journal of Urology. 103(4). 547–552. 4 indexed citations
8.
Wu, Xiu‐Xian, Yoshiyuki Kakehi, Xinghua Jin, Masashi Inui, & Mikio Sugimoto. (2008). Induction of Apoptosis in Human Renal Cell Carcinoma Cells by Vitamin E Succinate in Caspase-independent Manner. Urology. 73(1). 193–199. 6 indexed citations
9.
10.
Kong, Chuize, et al.. (2004). Increased expression of lung resistance‐related protein in lower grade urothelial carcinoma of the renal pelvis and ureter. International Journal of Urology. 11(9). 721–727. 5 indexed citations
11.
Wu, Xiu‐Xian, Osamu Ogawa, & Yoshiyuki Kakehi. (2004). Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.. PubMed. 24(6). 1489–97. 32 indexed citations
12.
Wu, Xiu‐Xian, Osamu Ogawa, & Yoshiyuki Kakehi. (2004). TRAIL and Chemotherapeutic Drugs in Cancer Therapy. Vitamins and hormones. 67. 365–383. 36 indexed citations
13.
Wu, Xiu‐Xian, Osamu Ogawa, & Yoshiyuki Kakehi. (2004). Sensitization of human renal cell carcinoma cell lines to TRAIL‐induced apoptosis by anthracyclines. International Journal of Urology. 11(3). 164–170. 1 indexed citations
14.
Wu, Xiu‐Xian, Yoshiyuki Kakehi, Youichi Mizutani, Toshiro Terachi, & Osamu Ogawa. (2001). Increased intracellular doxorubicin by anti-Fas monoclonal antibody: a mechanism that enhances the cytotoxicity in renal cell carcinoma cells. Urology. 57(5). 993–998. 10 indexed citations
15.
Wu, Xiu‐Xian, Yoshiyuki Kakehi, Yoichi Mizutani, et al.. (2001). Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. International Journal of Oncology. 19(1). 19–24. 37 indexed citations
16.
Wu, Xiu‐Xian, et al.. (2000). Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence. International Journal of Urology. 7(6). 210–217. 11 indexed citations
17.
Wu, Xiu‐Xian, Youichi Mizutani, Yoshiyuki Kakehi, Osamu Yoshida, & Osamu Ogawa. (2000). Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.. PubMed. 60(11). 2912–8. 67 indexed citations
18.
Wu, Xiu‐Xian, et al.. (1999). Deconvolution Analysis for Absorption and Metabolism of Aspirin in Microcapsules.. Biological and Pharmaceutical Bulletin. 22(11). 1212–1216. 2 indexed citations
19.
Wu, Xiu‐Xian, Yasuo Mizutani, Yoshiyuki Kakehi, et al.. (1998). [Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells, and effect of interferon-alpha and/or cimetidine on the expression].. PubMed. 44(9). 621–6. 4 indexed citations
20.
Akao, Toshiya, Yoshiyuki Kakehi, Xiu‐Xian Wu, et al.. (1997). Semi-quantitative analysis of telomerase activity of exfoliated cells in urine of patients with urothelial cancers:. Urologic Oncology Seminars and Original Investigations. 3(4). 118–124. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Malcolm Mason Breakdown of academic impact, for papers by Ralph A. Highshaw Breakdown of academic impact, for papers by Qingxiang Gao Breakdown of academic impact, for papers by Sam Tilborghs Breakdown of academic impact, for papers by Hannes Zwickl Breakdown of academic impact, for papers by Fengzhou Li Breakdown of academic impact, for papers by Lu Hao Breakdown of academic impact, for papers by Margaretha A. Skowron Breakdown of academic impact, for papers by Mingjing He
Rankless by CCL
2026